NICE - Endorsed Technology Appraisals 2007/2008

Technology Appraisals

Fully Endorsed

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA102 - Parent-training / education programmes in the management of children with conduct disorders - HSC (SQSD) (NICE) 12/08
​
National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA106 - Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C - HSC (SQSD) (NICE) 27/07​

• This guidance has been partially updated by NICE TA200 Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C, which was endorsed by DoH in November 2011. More information can be found on the website for TA106

​National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA110 - Follicular Lymphoma - Rituximab

• This guidance has been replaced by NICE TA243 - Rituximab for the first-line treatment of stage III-IV follicular lymphoma (Review of NICE TA110) which was endorsed by DoH in February 2012

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA112 - Breast Cancer (Early) - Hormonal Treatments - HSC (SQSD) (NICE) 28/07

• This guidance has been updated and replaced by NICE Clinical Guideline NG101 - Early and locally advanced breast cancer: diagnosis and management, which was endorsed by the DoH in September 2018.

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA113 - Inhaled Insulin for the Treatment of Diabetes Mellitus Types 1&2

• In January 2008, Pfizer ceased production of its inhaled insulin product Exubera. NICE technology appraisal 113 on inhaled insulin for diabetes (types I and II) has therefore been made obsolete. Pfizer have been letting doctors know that they should begin moving their patients off Exubera and onto other medicines that control high blood sugar levels. If you are worried about how you should control your blood sugar levels as a result of this announcement, you should contact your doctor as soon as possible to discuss your options for other blood sugar lowering medications.

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA114 - Drug Misuse - Methadone and Buprenorphine - HSC (SQSD) (NICE) 14/07

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA115 - Drug Misuse - Naltrexone - HSC (SQSD) (NICE) 15/07

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA116 - Breast Cancer - Gemcitabine - HSC (SQSD) (NICE) 29/07

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA117 - Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis - HSC (SQSD) (NICE) 31/07

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA118 - Colorectal Caner - Bevacizumab & Cetuximab - HSC (SQSD) (NICE) 16/07

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA119 - Fludarabine monotherapy for the first-line treatment of Chronic Lymphocytic Leukaemia (CLL) - HSC (SQSD) (NICE) 30/07

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA120 - Heart Failure - Cardiac Resynchronisation - HSC (SQSD) (NICE) 08/08

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA121 - Carmustine implants and temolozomide for glioma - HSC (SQSD) (NICE) 09/08

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA122 - Alteplase for the treatment of Acute Ischaemic Stroke

• This guidance has been replaced TA 264 - Alteplase for treating acute ischaemic stroke (review of technology appraisal guidance 122) , which was endorsed by DoH in October 2012

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA125 - Adalimumab for the treatment of psoriatic arthritis

• This guidance has been replaced by NICE TA199 Psoriatic arthritis - etanercept, infliximab and adalimumab, which was endorsed by DoH in December 2011

​National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA127 - Multiple Sclerosis - Natalizumab - HSC (SQSD) (NICE) 04/08

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA128 - Stapled haemorroidopexy for the treatment of haemorrhoids - HSC (SQSD) (NICE) 14/08

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA129 - Multiple myeloma - bortezomib monotherapy - HSC (SQSD) (NICE) 10/08

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA132 - Ezetimibe for the treatment of hypercholesterolaemia

• This guidance has been updated and replaced by TA 385 - Ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia, which was endorsed by the DoH in March 2016.

National Institute for National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA133 - Omalizumab for severe persistent allergic asthma

• This guidance has been replaced by TA 278 - Omalizumab for the treatment of severe persistent allergic asthma in children aged 6 and over and adults which was endorsed by DoH in May 2013.

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA135 - Pemetrexed disodium for the treatment of malignant pleural mesothelioma - HSC (SQSD) (NICE) 11/08